Technical Analysis for TERN - Terns Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 5.60 -5.25% -0.31
TERN closed down 5.25 percent on Wednesday, November 20, 2024, on 82 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -5.25%
Inside Day Range Contraction -5.25%
Below Lower BB Weakness -5.25%

   Recent Intraday Alerts

Alert Time
Down 5% about 17 hours ago
Fell Below Previous Day's Low about 17 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Down 3% about 18 hours ago
Possible NR7 about 18 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Terns Pharmaceuticals, Inc. Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Glucagon Bile Acid Chronic Liver Diseases Anti Diabetic Drugs

Is TERN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.4
52 Week Low 3.59
Average Volume 1,513,986
200-Day Moving Average 7.14
50-Day Moving Average 7.75
20-Day Moving Average 6.74
10-Day Moving Average 6.57
Average True Range 0.48
RSI (14) 29.08
ADX 25.96
+DI 11.04
-DI 31.16
Chandelier Exit (Long, 3 ATRs) 6.19
Chandelier Exit (Short, 3 ATRs) 7.00
Upper Bollinger Bands 7.76
Lower Bollinger Band 5.71
Percent B (%b) -0.05
BandWidth 30.49
MACD Line -0.45
MACD Signal Line -0.33
MACD Histogram -0.1121
Fundamentals Value
Market Cap 346.05 Million
Num Shares 61.8 Million
EPS -1.15
Price-to-Earnings (P/E) Ratio -4.87
Price-to-Sales 302.64
Price-to-Book 1.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.14
Resistance 3 (R3) 6.19 6.05 6.05
Resistance 2 (R2) 6.05 5.92 6.03 6.02
Resistance 1 (R1) 5.83 5.83 5.76 5.78 5.99
Pivot Point 5.69 5.69 5.66 5.67 5.69
Support 1 (S1) 5.47 5.56 5.40 5.42 5.21
Support 2 (S2) 5.33 5.47 5.31 5.18
Support 3 (S3) 5.11 5.33 5.15
Support 4 (S4) 5.06